Study of Givinostat in people with Duchenne muscular dystrophy
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital clinical trials.
This study is for people with Duchenne muscular dystrophy (DMD) who are taking Givinostat, a daily oral medicine. Researchers will look at real-world data to see how the medicine works in everyday life, including lab results and how it's being used.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 6 years old.
- You have been diagnosed with Duchenne muscular dystrophy (DMD) through genetic testing.
- Your doctor has prescribed Givinostat (an oral medication) for you.
- You started taking Givinostat no more than 6 months before joining this study.
- If you have already started Givinostat, you have not stopped taking it permanently.
- Your medical records include information about your DMD diagnosis, Givinostat dose, and lab results (blood tests for triglycerides and blood cell counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new medicine called AOC 1044 (delpacibart zotadirsen) can help boys with Duchenne muscular dystrophy (DMD) who have a specific genetic mutation. The medicine works by helping the body skip a damaged part of the gene to make a functional protein.
This study follows people with Duchenne muscular dystrophy (DMD) who are taking eteplirsen, golodirsen, or casimersen. It aims to understand how these medicines work in everyday life over a long period.
This trial looks at how safely givinostat works over a longer time in people with Duchenne muscular dystrophy (DMD). It mainly checks long-term side effects and tolerability, especially in a specific subgroup of muscle fat levels.
This trial tests an experimental drug called givinostat in boys ages 2 to under 6 years with Duchenne muscular dystrophy (DMD). The study looks at how the drug works in the body and if it is safe, with the goal of finding new treatment options for young children.
This Phase 3 trial tests givinostat to see if it can improve safety and functional outcomes in boys with Duchenne muscular dystrophy who cannot walk. You might be a candidate if you meet age, genetic diagnosis, wheelchair-level mobility, and specific arm-strength/respiratory/heart criteria.
This study invites people with Duchenne muscular dystrophy (DMD) and their caregivers to share their experiences through interviews. It focuses on those who have been taking the medication Givinostat for at least two years, or caregivers of patients with limited arm movement.
Hear when a new Duchene Muscular Dystrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.